In vivo CRISPR screens identify the glutamine transporter SLC1A5 as a metabolic barrier to antitumor immunity
Science Immunology · 2026
DOI: 10.1126/sciimmunol.aea4179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, 2026. Verfasst von Wenlong Jia und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Amino Acid Transport System ASC, Minor Histocompatibility Antigens, Neoplasms. Die Arbeit nennt 92 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Huazhong University of Science and Technology.
Abstract (Originalsprache)
Tumor cells often evade immune pressure via metabolic reprogramming, yet the key metabolic regulators orchestrating this process remain incompletely defined. Here, using in vivo metabolic CRISPR screening under distinct immune pressures, we identified tumor cell–intrinsic solute carrier family 1 member 5 (SLC1A5) as a metabolic node that sustains an immunosuppressive tumor microenvironment. SLC1A5-mediated glutamine metabolism in tumor cells modulated CD8 T cell infiltration and effector function, reshaping tumor responses to immune checkpoint blockade therapy. Glucose deprivation up-regulated SLC1A5 isoforms in tumor cells, enhancing glutamine uptake and glutathione synthesis. This adaptation limited mitochondrial oxidative stress and cytosolic mitochondrial DNA release, thereby suppressing cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) activation, interferon-β production, and CD8 T cell antitumor responses. These findings define a glutamine-fueled metabolic program as a barrier to tumor immunogenicity, positioning SLC1A5 as a tumor-intrinsic metabolic regulator with potential therapeutic relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Clinical Medical Research Center for Hepatic Surgery of Hubei Province, Wuhan, China.
- Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, China.
- Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
ORCID-Profile: Wenlong Jia, Guanxing Yu, Shenqi Han, Zhibo Ma, Junnan Liang, Wei Yan, Chenglong Zeng, Lin Xue, Feng Xia, Peixiang Lan, Wei Yan, Wanguang Zhang, Huifang Liang, Xiaoping Chen, Zhao Huang, Bixiang Zhang
Förderung
- National Natural Science Foundation of China
- Huazhong University of Science and Technology
Zitieren
APA
Jia, W., Yu, G., Han, S., Ma, Z., Liang, J., Yan, W., Zhang, X., Zeng, C., Xue, L., Xia, F., Li, G., Tao, R., Lan, P., Yan, W., Zhang, W., Liang, H., Chen, X., Huang, Z., & Zhang, B. (2026). In vivo CRISPR screens identify the glutamine transporter SLC1A5 as a metabolic barrier to antitumor immunity. Science Immunology. https://doi.org/10.1126/sciimmunol.aea4179
Vancouver
Jia W, Yu G, Han S, Ma Z, Liang J, Yan W, et al. In vivo CRISPR screens identify the glutamine transporter SLC1A5 as a metabolic barrier to antitumor immunity. Science Immunology. 2026. doi:10.1126/sciimmunol.aea4179
BibTeX
@article{Jia2026,
author = {Jia, Wenlong and Yu, Guanxing and Han, Shenqi and Ma, Zhibo and Liang, Junnan and Yan, Wei and Zhang, Xinling and Zeng, Chenglong and Xue, Lin and Xia, Feng and Li, Ganxun and Tao, Ran and Lan, Peixiang and Yan, Wei and Zhang, Wanguang and Liang, Huifang and Chen, Xiaoping and Huang, Zhao and Zhang, Bixiang},
title = {In vivo CRISPR screens identify the glutamine transporter SLC1A5 as a metabolic barrier to antitumor immunity},
journal = {Science Immunology},
year = {2026},
doi = {10.1126/sciimmunol.aea4179}
}
EUVIMED